This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.
Downloadable materials for your patients
Below are links to downloadable materials that may be useful as a resource to pass onto your patients who have been prescribed Venetoclax.
Patient guide for VEN + O
UK-VNCCLL-260224
Patient guide for VEN + R
UK-VNCCLL-260225
Patient guide for VEN+A
UK-VNCCLL-260007
Patient guide for VEN + I
UK-VNCCLL-260226
VEN+O dosing chart
UK-VNCCLL-260227
Ven+R dosing chart
UK-VNCCLL-260228
VEN+A dosing chart
UK-VNCCLL-260010
VEN+I dosing chart
UK-VNCCLL-260229
1L, 1st line; A, acalabrutinib; CLL, Chronic lymphocytic leukaemia; I, Ibrutinib; O, Obinutuzumab; R, Rituximab; R/R, Relapsed/Refractory; VEN, VENCLYXTO.
You are advised to read the Prescribing Information and Summary of Product Characteristics to evaluate patient suitability for VENCLYXTO.
VENCLYXTO PRESCRIBING INFORMATION
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS
UK-VNCCLL-260258. Date of preparation: July 2026.
